Q1 2026 recap: 6 FDA approvals pediatricians need to know

The first quarter of 2026 marked a period of profound advancement in pediatric health care, driven by a wave of FDA drug approvals that offer renewed hope for some of the most complex and rare pediatric conditions. From historic, first-of-their-kind systemic therapies for ultrarare disorders such as Menkes disease and Hunter syndrome to critical new interventions for achondroplasia and acquired hypothalamic obesity, these regulatory milestones represent monumental strides in pediatric disease management.